LifeStance Health Group (NASDAQ:LFST) Raised to Buy at Wall Street Zen

Key Points

• LifeStance Health Group has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting a growing confidence in the company's stock performance.
• Recently, several research reports have set new price targets for LifeStance, with UBS Group raising their target from $8.50 to $9.00, while the consensus price target remains at $8.50.
• The company reported a quarterly revenue of $345.31 million, exceeding expectations and indicating a year-over-year revenue growth of 10.6%.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

LFST has been the subject of several other research reports. UBS Group lifted their price objective on LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research note on Friday. BTIG Research began coverage on LifeStance Health Group in a research note on Friday, July 25th. They set a "buy" rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, LifeStance Health Group currently has an average rating of "Moderate Buy" and a consensus price target of $8.50.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $4.37 on Friday. The stock has a market cap of $1.70 billion, a PE ratio of -87.40 and a beta of 1.13. LifeStance Health Group has a fifty-two week low of $3.74 and a fifty-two week high of $8.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.47. The stock has a fifty day moving average of $4.77 and a 200-day moving average of $6.20.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $345.31 million during the quarter, compared to analysts' expectations of $345.05 million. LifeStance Health Group had a negative return on equity of 1.12% and a negative net margin of 1.23%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) earnings per share. Equities research analysts anticipate that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Transactions at LifeStance Health Group

In related news, insider Ujjwal Ramtekkar sold 16,000 shares of LifeStance Health Group stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $5.94, for a total transaction of $95,040.00. Following the completion of the sale, the insider owned 113,435 shares of the company's stock, valued at approximately $673,803.90. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.20% of the company's stock.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds have recently added to or reduced their stakes in LFST. Parcion Private Wealth LLC bought a new stake in LifeStance Health Group during the first quarter worth about $15,670,000. Dimensional Fund Advisors LP lifted its stake in LifeStance Health Group by 87.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock worth $25,977,000 after purchasing an additional 1,643,390 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in LifeStance Health Group during the first quarter worth about $7,932,000. Nuveen LLC bought a new stake in LifeStance Health Group during the first quarter worth about $6,928,000. Finally, Landscape Capital Management L.L.C. bought a new stake in LifeStance Health Group during the first quarter worth about $5,135,000. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.